[go: up one dir, main page]

JPH083143A - Production of 6-aralkyl substituted pyrimidine derivative - Google Patents

Production of 6-aralkyl substituted pyrimidine derivative

Info

Publication number
JPH083143A
JPH083143A JP6139021A JP13902194A JPH083143A JP H083143 A JPH083143 A JP H083143A JP 6139021 A JP6139021 A JP 6139021A JP 13902194 A JP13902194 A JP 13902194A JP H083143 A JPH083143 A JP H083143A
Authority
JP
Japan
Prior art keywords
group
aralkyl
pyrimidine derivative
atom
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6139021A
Other languages
Japanese (ja)
Inventor
Masaru Ubasawa
賢 姥澤
Hideaki Takashima
秀昭 高嶋
Koichi Sekiya
浩一 関谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Priority to JP6139021A priority Critical patent/JPH083143A/en
Publication of JPH083143A publication Critical patent/JPH083143A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain the subject compound useful as an antiviral agent, especially an antiretrovirus agent in high purity and yield by reducing a specific pyrimidine derivative in the presence of a metal or its salt and an acid. CONSTITUTION:This method for producing a 6-aralkyl substituted pyrimidine derivative of formula II {R<1> is H, a halogen, a 1-5C alkyl, a 3-8C cycloalkyl, etc.; R<2> is H, a 1-5C alkyl or a (substituted) 7-12C aralkyl; R<3> is H or a group of (CH2)n-R<6>R<7> [R<6> is O, S or methylene; R<7> is H or a 1-5C alkyl; (n) is 0 or 1]; R<4> is a (substituted)6-10C aryl; X and Y are independently each O or S} (e.g. 6-benzyl-1-ethoxymethyl-5-isopropyluracil) is to reduce a pyrimidine derivative of formula I (R<5> is H or a 1-6C acyl) in the presence of a metal (preferably Zn) or its salt and an acid. The formation of by-products according to a well- known method is suppressed by the method.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、6−アラルキル置換ピ
リミジン誘導体の製造方法に関し、詳細には抗ウイルス
剤、特に抗レトロウイルス剤として有用な6−アラルキ
ル置換ピリミジン誘導体の新規な合成方法に関する。
TECHNICAL FIELD The present invention relates to a method for producing a 6-aralkyl-substituted pyrimidine derivative, and more particularly to a novel method for synthesizing a 6-aralkyl-substituted pyrimidine derivative useful as an antiviral agent, particularly as an antiretroviral agent.

【0002】[0002]

【従来の技術および発明が解決しようとする課題】近
年、レトロウイルスの1種であるヒト後天性免疫不全症
ウイルス(HIV)感染症が大きな社会問題となってい
る。本発明者らの一部は、先に6−置換アシクロピリミ
ジンヌクレオシド系化合物に抗HIV作用等の抗レトロ
ウイルス活性を見出している(WO89/09213
号、特開平3−279366号、特開平3−28467
0号公報)。これらの6−置換アシクロピリミジンヌク
レオシド系化合物のうち、6−アラルキル置換アシクロ
ピリミジンヌクレオシド類は抗ウイルス活性と水溶性の
バランスが良く、医薬品としての好ましい特性とその合
成方法(Mol.Pharmacol.,44,895
−900(1993))が知られている。例えば、6−
ベンジル−1−エトキシメチル−5−エチルウラシルは
下記の方法で合成される。
2. Description of the Related Art In recent years, human acquired immunodeficiency virus (HIV) infection, which is one of retroviruses, has become a major social problem. Some of the present inventors have previously found that 6-substituted acyclopyrimidine nucleoside compounds have antiretroviral activity such as anti-HIV action (WO89 / 09213).
JP-A-3-279366, JP-A-3-28467
No. 0). Among these 6-substituted acyclopyrimidine nucleoside compounds, 6-aralkyl-substituted acyclopyrimidine nucleosides have a good balance of antiviral activity and water solubility, and have favorable properties as pharmaceuticals and their synthetic method (Mol. Pharmacol. 44,895
-900 (1993)) is known. For example, 6-
Benzyl-1-ethoxymethyl-5-ethyluracil is synthesized by the following method.

【0003】[0003]

【化3】 Embedded image

【0004】(上記式中でMは金属を表す。) すなわち、1−エトキシメチル−5−エチルウラシルに
n−アルキルリチウム、リチウムジイソプロピルアミド
(LDA)、リチウム−2,2,6,6−テトラメチル
ピペリジド(LTMP)、ポタシウムビストリメチルシ
リルアミド、ソジウムビストリメチルシリルアミド等の
有機アルカリ金属を作用させ、得られた1−エトキシエ
チル−5−エチルウラシルのアルカリ金属塩にベンズア
ルデヒドを反応させ、得られた1−エトキシメチル−6
−(α−ヒドロキシベンジル)−5−エチルウラシルを
パラジウム炭素または水酸化パラジウムの存在下で水素
と反応させることによりヒドロキシル基を水素原子に還
元させる。
(M in the above formula represents a metal.) That is, 1-ethoxymethyl-5-ethyluracil, n-alkyllithium, lithium diisopropylamide (LDA), lithium-2,2,6,6-tetra An organic alkali metal such as methyl piperidide (LTMP), potassium bistrimethylsilylamide, sodium bistrimethylsilylamide, etc. is allowed to act, and the obtained alkali metal salt of 1-ethoxyethyl-5-ethyluracil is reacted with benzaldehyde to obtain 1-ethoxymethyl-6
The hydroxyl group is reduced to a hydrogen atom by reacting-(α-hydroxybenzyl) -5-ethyluracil with hydrogen in the presence of palladium on carbon or palladium hydroxide.

【0005】しかし、この方法では目的とする化合物の
他にピリミジン環の5位および6位が水添されたジヒド
ロ体が副生し、収率の低下を招くと同時に製品の純度が
低下するという問題があった。そこで副生物の生成を抑
え、高純度6−アラルキル置換ピリミジン誘導体を得る
方法の開発が望まれていた。
However, in this method, in addition to the target compound, a dihydro body in which the 5- and 6-positions of the pyrimidine ring are hydrogenated is by-produced, which leads to a decrease in yield and a decrease in product purity. There was a problem. Therefore, development of a method for obtaining a highly pure 6-aralkyl-substituted pyrimidine derivative while suppressing generation of by-products has been desired.

【0006】[0006]

【問題を解決するための手段】本発明者らは、上記課題
を解決するために鋭意検討を重ねた結果、特定の条件下
で6−(α−ヒドロキシアラルキル)−ピリミジン誘導
体を還元することにより、副生物の生成を抑え、かつ高
純度の6−アラルキル置換ピリミジン誘導体が得られる
ことを見出し、本発明を完成するに至った。
Means for Solving the Problems As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that by reducing a 6- (α-hydroxyaralkyl) -pyrimidine derivative under specific conditions. The inventors have found that a 6-aralkyl-substituted pyrimidine derivative of high purity can be obtained while suppressing the production of by-products, and completed the present invention.

【0007】即ち、本発明の要旨は、下記一般式(I)That is, the gist of the present invention is the following general formula (I)

【0008】[0008]

【化4】 [Chemical 4]

【0009】(上記式中で、R1は水素原子,ハロゲン
原子,C1〜C5のアルキル基,C3〜C 8のシクロアルキ
ル基,C2〜C6のアシル基または置換基を有してもよい
2〜C 6のアルケニル基、C2〜C6のアルキニル基、C
7〜C12のアリールカルボニル基、C8〜C12のアリール
カルボニルアルキル基、C6〜C10のアリールチオ基も
しくはC7〜C12のアラルキル基を表し、R2は水素原
子、C1〜C5のアルキル基または置換基を有してもよい
7〜C12のアラルキル基を表し、R3は水素原子または
−(CH2n−R67で表される基(R6は酸素原子、
硫黄原子またはメチレン基を表し、R7は水素原子また
は置換基を有してもよいC1〜C5のアルキル基を表し、
nは0または1の整数を表す。)を表し、R4は置換基
を有してもよいC6〜C10のアリール基を表し、R5は水
素原子またはC2〜C6のアシル基を表し、XおよびYは
それぞれ独立して酸素原子または硫黄原子を表す。)で
表されるピリミジン誘導体を金属またはその塩および酸
の存在下で還元することを特徴とする下記一般式(II)
(In the above formula, R1Is hydrogen atom, halogen
Atom, C1~ CFiveAlkyl group of C3~ C 8Cycloarch
Lu group, C2~ C6May have an acyl group or a substituent of
C2~ C 6Alkenyl group of C2~ C6An alkynyl group of C
7~ C12Arylcarbonyl group of C8~ C12Aryl
Carbonylalkyl group, C6~ CTenThe arylthio group of
It is C7~ C12Represents an aralkyl group of R2Is hydrogen
Child, C1~ CFiveMay have an alkyl group or a substituent of
C7~ C12Represents an aralkyl group of R3Is a hydrogen atom or
-(CH2)n-R6R7A group represented by (R6Is an oxygen atom,
Represents a sulfur atom or a methylene group, R7Is a hydrogen atom
Is C which may have a substituent1~ CFiveRepresents an alkyl group of
n represents an integer of 0 or 1. ), RFourIs a substituent
May have C6~ CTenRepresents an aryl group of RFiveIs water
Elementary atom or C2~ C6Represents an acyl group of X and Y are
Each independently represents an oxygen atom or a sulfur atom. )so
The represented pyrimidine derivative is a metal or its salt and an acid.
The following general formula (II) is characterized by being reduced in the presence of

【0010】[0010]

【化5】 Embedded image

【0011】(上記式中で、R1、R2、R3、R4、Xお
よびYは既に定義したとおりである。)で表される6−
アラルキル置換ピリミジン誘導体の製造方法に存する。
上記一般式(I)および(II)で表される化合物で、R
1のC2〜C6のアルケニル基は、ハロゲン原子、シアノ
基、C6〜C10のアリール基、C2〜C6のアルコキシカ
ルボニル基またはカルバモイル基を置換基として有して
もよく、C2〜C6のアルキニル基はC6〜C10のアリー
ル基を置換基として有してもよく、C7〜C12のアリー
ルカルボニル基、C8〜C12のアリールカルボニルアル
キル基、C6〜C10のアリールチオ基およびC7〜C12
アラルキル基のそれぞれはハロゲン原子、C1〜C5のア
ルキル基またはC1〜C5のアルコキシ基を置換基として
有していてもよい。
(In the above formula, R 1 , R 2 , R 3 , R 4 , X and Y are as defined above) 6-
It exists in a method for producing an aralkyl-substituted pyrimidine derivative.
In the compounds represented by the above general formulas (I) and (II), R
1 alkenyl group C 2 -C 6 represents a halogen atom, a cyano group, an aryl group of C 6 -C 10, may have a alkoxycarbonyl group or a carbamoyl group of C 2 -C 6 as substituent groups, C alkynyl group 2 -C 6 may have as a substituent an aryl group of C 6 -C 10, an arylcarbonyl group C 7 -C 12, arylcarbonylalkyl group C 8 ~C 12, C 6 ~ Each of the C 10 arylthio group and the C 7 to C 12 aralkyl group may have a halogen atom, a C 1 to C 5 alkyl group or a C 1 to C 5 alkoxy group as a substituent.

【0012】R2のC7〜C12のアラルキル基は、ハロゲ
ン原子、C1〜C5のアルキル基またはC1〜C5のアルコ
キシ基を置換基として有してもよい。R3の−(CH2
n−R67で表される基で、R7のC1〜C5のアルキル基
は、ハロゲン原子,ヒドロキシル基,6員環含窒素カル
ボニルオキシ基,ホルミルオキシ基,C2〜C6のアルキ
ルカルボニルオキシ基,C4〜C9のシクロアルキルカル
ボニルオキシ基,C8〜C13のアラルキルカルボニルオ
キシ基,C7〜C12のアリールカルボニルオキシ基,ア
ジド基またはハロゲン原子、C6〜C10のアリール基、
1〜C5のアルキル基、C1〜C5のアルコキシ基、C1
〜C3のハロアルキル基等を置換基として有してもよい
2〜C6のアルコキシカルボニルオキシ基,C2〜C6
N−アルキルカルバモイルオキシ基,C7〜C12のN−
アリールカルバモイルオキシ基,C2〜C6のN−アルキ
ルチオカルバモイルオキシ基,C7〜C12のN−アリー
ルチオカルバモイルオキシ基,C1〜C5のアルコキシ
基,C7〜C12のアラルキルオキシ基,C6〜C10の分岐
アルキル基、C3〜C8のシクロアルキル基もしくはC6
〜C10のアリール基を置換基として有してもよい。
The C 7 -C 12 aralkyl group of R 2 may have a halogen atom, a C 1 -C 5 alkyl group or a C 1 -C 5 alkoxy group as a substituent. R 3- (CH 2 )
a group represented by n -R 6 R 7, alkyl C 1 -C 5 of R 7 is halogen atom, a hydroxyl group, 6-membered ring nitrogen-containing carbonyl group, formyloxy group, C 2 -C 6 Alkylcarbonyloxy group, C 4 -C 9 cycloalkylcarbonyloxy group, C 8 -C 13 aralkylcarbonyloxy group, C 7 -C 12 arylcarbonyloxy group, azido group or halogen atom, C 6 -C 10 aryl groups,
C 1 -C 5 alkyl group, C 1 -C 5 alkoxy group, C 1
To C 3 haloalkyl group and the like may have a C 2 to C 6 alkoxycarbonyloxy group, C 2 to C 6 N-alkylcarbamoyloxy group, C 7 to C 12 N-.
Arylcarbamoyloxy group, C 2 -C 6 of N- alkylthiocarbamoyl group, N- arylthiocarbamoyl group of C 7 ~C 12, C 1 ~C alkoxy group 5, aralkyloxy group C 7 -C 12 , A C 6 -C 10 branched alkyl group, a C 3 -C 8 cycloalkyl group or C 6
An aryl group having -C 10 which may have a substituent.

【0013】R4のC6〜C10のアリール基は、ハロゲン
原子、C1〜C5のアルキル基またはC1〜C5のアルコキ
シ基を置換基として有してもよい。上記一般式(I)お
よび(II)で表される化合物のうちでは、R1がメチル
基、エチル基、n−プロピル基、i−プロピル基、n−
ブチル基、t−ブチル基、n−ペンチル基等のC1〜C5
のアルキル基を表し、R2が水素原子を表し、R3が−C
2−R67で表される基(R6は酸素原子を表し、R7
がメチル基またはヒドロキシルメチル基を表す。)を表
し、R4がフェニル基、キシリル基等のアリール基を表
す化合物が好ましい。
The C 6 -C 10 aryl group of R 4 may have a halogen atom, a C 1 -C 5 alkyl group or a C 1 -C 5 alkoxy group as a substituent. Among the compounds represented by the above general formulas (I) and (II), R 1 is methyl group, ethyl group, n-propyl group, i-propyl group, n-
C 1 -C 5, such as butyl, t- butyl group, n- pentyl group
Represents an alkyl group, R 2 represents a hydrogen atom, and R 3 represents -C.
A group represented by H 2 —R 6 R 7 (R 6 represents an oxygen atom, R 7
Represents a methyl group or a hydroxylmethyl group. And a compound in which R 4 represents an aryl group such as a phenyl group or a xylyl group is preferable.

【0014】上記一般式(II)で表される6−アラルキ
ル置換ピリミジン誘導体は、上記一般式(I)で表され
るピリミジン誘導体をメタノール、エタノール等のアル
コール類、アセトニトリル、テトラヒドロフラン(TH
F)、ジメチルホルムアミド、ジオキサン、ピリミジン
等の適当な溶媒中、亜鉛、スズ、塩化第2スズ、鉄、ア
ルミニウム、マグネシウム等の金属またはそれらの塩お
よび塩酸、酢酸等の酸と反応させて得られる。上記金属
としては、亜鉛を用いることが好ましい。反応温度は特
に制限されないが10〜100℃で反応させることが好
ましい。得られた6−アラルキル置換ピリミジ誘導体は
通常のヌクレオシド等の分離精製方法、例えば再結晶、
吸着若しくはイオン交換クロマトグラフィー等を適宜選
択して分離精製できる。
The 6-aralkyl-substituted pyrimidine derivative represented by the general formula (II) is obtained by converting the pyrimidine derivative represented by the general formula (I) into alcohols such as methanol and ethanol, acetonitrile, tetrahydrofuran (TH).
F), dimethylformamide, dioxane, pyrimidine, etc. in a suitable solvent, and obtained by reacting with a metal such as zinc, tin, stannic chloride, iron, aluminum, magnesium or a salt thereof and an acid such as hydrochloric acid, acetic acid, etc. . It is preferable to use zinc as the metal. The reaction temperature is not particularly limited, but the reaction is preferably performed at 10 to 100 ° C. The obtained 6-aralkyl-substituted pyrimidi derivative is purified by a conventional method for separating and purifying nucleosides, for example, recrystallization,
It can be separated and purified by appropriately selecting adsorption or ion exchange chromatography.

【0015】[0015]

【実施例】以下、本発明を実施例により更に詳細に説明
するが、本発明はその要旨を越えない限り以下の実施例
により限定されるものではない。 実施例1 6−ベンジル−1−エトキシメチル−5−イソプロピル
ウラシルの合成 1−エトキシメチル−6−(α−ヒドロキシベンジル)
−5−イソプロピルウラシル3.18gをアセトニトリ
ル20mlに溶解し、次いで亜鉛末6gと濃塩酸20m
lを加え、室温で2時間撹拌した。これに水50mlを
加え、酢酸エチル20mlにて3回抽出した。有機層を
重ソウ水で洗い中和し、減圧濃縮した後、残留物をエタ
ノール5mlに溶解し0〜4℃で結晶化し、標記化合物
(収率89%、融点109〜110℃)を得た。
The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to the following examples unless it exceeds the gist thereof. Example 1 Synthesis of 6-benzyl-1-ethoxymethyl-5-isopropyluracil 1-ethoxymethyl-6- (α-hydroxybenzyl)
3.18 g of -5-isopropyluracil was dissolved in 20 ml of acetonitrile, then 6 g of zinc powder and 20 m of concentrated hydrochloric acid.
1 was added, and the mixture was stirred at room temperature for 2 hours. 50 ml of water was added thereto, and the mixture was extracted 3 times with 20 ml of ethyl acetate. The organic layer was washed with deuterium oxide water, neutralized, and concentrated under reduced pressure. The residue was dissolved in 5 ml of ethanol and crystallized at 0 to 4 ° C to obtain the title compound (yield 89%, melting point 109 to 110 ° C). .

【0016】実施例2 6−ベンジル−1−エトキシメチル−5−イソプロピル
ウラシルの合成 実施例1において、原料として6−(α−アセトキシベ
ンジル)−1−エトキシメチル−5−イソプロピルウラ
シル3.6gを用いて、実施例1と同様の反応を行い、
標記化合物(収率87%)を得た。 実施例3 6−ベンジル−1−エトキシメチル−5−イソプロピル
ウラシルの合成 1−エトキシメチル−6−(α−ヒドロキシベンジル)
−5−イソプロピルウラシル3.18gを酢酸20ml
に溶解し、次いで亜鉛末6gを加え、還流温度で16時
間撹拌した。水50mlを加え、酢酸エチル20mlで
3回抽出した。有機層を重ソウ水で洗い中和し、減圧濃
縮した後、残留物をエタノール5mlに溶解し0〜4℃
で結晶化し、標記化合物(収率88%)を得た。 実施例4 実施例1と同様な方法で種々の6−アラルキル置換ピリ
ミジン誘導体を収率87〜90%で得た。得られた化合
物を表1に示す。
Example 2 Synthesis of 6-benzyl-1-ethoxymethyl-5-isopropyluracil In Example 1, 3.6 g of 6- (α-acetoxybenzyl) -1-ethoxymethyl-5-isopropyluracil was used as a raw material. Using the same reaction as in Example 1,
The title compound (yield 87%) was obtained. Example 3 Synthesis of 6-benzyl-1-ethoxymethyl-5-isopropyluracil 1-Ethoxymethyl-6- (α-hydroxybenzyl)
-5-isopropyl uracil 3.18 g acetic acid 20 ml
And zinc powder 6 g were added, followed by stirring at reflux temperature for 16 hours. 50 ml of water was added, and the mixture was extracted 3 times with 20 ml of ethyl acetate. The organic layer was washed with deuterium oxide water, neutralized, and concentrated under reduced pressure. The residue was dissolved in 5 ml of ethanol and the temperature was 0 to 4 ° C.
Was crystallized to give the title compound (yield 88%). Example 4 In the same manner as in Example 1, various 6-aralkyl-substituted pyrimidine derivatives were obtained with a yield of 87 to 90%. The compounds obtained are shown in Table 1.

【0017】[0017]

【表1】 [Table 1]

【0018】比較例1 水酸化パラジウムカーボンを用いた還元方法 1−エトキシメチル−6−(α−ヒドロキシベンジル)
−5−エチルウラシル3.18gをジオキサン17m
l、エタノール9ml、酢酸3mlに溶解し、水酸化パ
ラジウムカーボン0.43gの存在下、水素雰囲気下で
60℃、72時間撹拌した。ここで反応液の一部を液体
クロマトグラフィ−で調べたところ約10%の副生物を
含んでいた。72時間撹拌後、水酸化パラジウムカーボ
ンを濾去し、濾液を濃縮した。残留物をエタノールから
結晶化し、目的物の6−ベンジル−1−エトキシメチル
−5−エチルウラシル1.37g(収率45%)を得
た。
Comparative Example 1 Reduction Method Using Palladium Hydroxide Carbon 1-Ethoxymethyl-6- (α-hydroxybenzyl)
3.18 g of -5-ethyluracil was added to 17 m of dioxane.
1, ethanol (9 ml) and acetic acid (3 ml), and the mixture was stirred in the presence of 0.43 g of palladium hydroxide carbon under a hydrogen atmosphere at 60 ° C. for 72 hours. When a part of the reaction solution was examined by liquid chromatography, it contained about 10% by-products. After stirring for 72 hours, palladium hydroxide carbon was filtered off and the filtrate was concentrated. The residue was crystallized from ethanol to obtain 1.37 g (yield 45%) of 6-benzyl-1-ethoxymethyl-5-ethyluracil, which was the target substance.

【0019】[0019]

【発明の効果】本発明の方法によれば、抗ウイルス剤と
して有用な6−アラルキル置換ピリミジン誘導体を高純
度かつ高収率で製造することができる。
EFFECTS OF THE INVENTION According to the method of the present invention, a 6-aralkyl-substituted pyrimidine derivative useful as an antiviral agent can be produced with high purity and high yield.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】下記一般式(I) 【化1】 (上記式中で、R1は水素原子,ハロゲン原子,C1〜C
5のアルキル基,C3〜C 8のシクロアルキル基,C2〜C
6のアシル基または置換基を有してもよいC2〜C 6のア
ルケニル基、C2〜C6のアルキニル基、C7〜C12のア
リールカルボニル基、C8〜C12のアリールカルボニル
アルキル基、C6〜C10のアリールチオ基もしくはC7
12のアラルキル基を表し、R2は水素原子、C1〜C5
のアルキル基または置換基を有してもよいC7〜C12
アラルキル基を表し、R3は水素原子または−(CH2
n−R67で表される基(R6は酸素原子、硫黄原子また
はメチレン基を表し、R7は水素原子または置換基を有
してもよいC1〜C5のアルキル基を表し、nは0または
1の整数を表す。)を表し、R4は置換基を有してもよ
いC6〜C10のアリール基を表し、R5は水素原子または
2〜C6のアシル基を表し、XおよびYはそれぞれ独立
して酸素原子または硫黄原子を表す。)で表されるピリ
ミジン誘導体を金属またはその塩および酸の存在下で還
元することを特徴とする下記一般式(II) 【化2】 (上記式中で、R1、R2、R3、R4、XおよびYは既に
定義したとおりである。)で表される6−アラルキル置
換ピリミジン誘導体の製造方法。
1. The following general formula (I):(In the above formula, R1Is hydrogen atom, halogen atom, C1~ C
FiveAlkyl group of C3~ C 8Cycloalkyl group, C2~ C
6C which may have an acyl group or a substituent2~ C 6A
Lucenyl group, C2~ C6An alkynyl group of C7~ C12A
Reel carbonyl group, C8~ C12Aryl carbonyl
Alkyl group, C6~ CTenArylthio group or C7~
C12Represents an aralkyl group of R2Is a hydrogen atom, C1~ CFive
C which may have an alkyl group or a substituent7~ C12of
Represents an aralkyl group, R3Is a hydrogen atom or-(CH2)
n-R6R7A group represented by (R6Is an oxygen atom, a sulfur atom or
Represents a methylene group, R7Has a hydrogen atom or a substituent
May be C1~ CFiveRepresents an alkyl group, and n is 0 or
Represents an integer of 1. ), RFourMay have a substituent
I C6~ CTenRepresents an aryl group of RFiveIs a hydrogen atom or
C2~ C6Represents an acyl group, and X and Y are independent
And represents an oxygen atom or a sulfur atom. ) Represented by
Reduction of a midine derivative in the presence of metal or its salt and acid
The following general formula (II) is characterized by(In the above formula, R1, R2, R3, RFour, X and Y are already
As defined. ) 6-aralkyl device represented by
A method for producing a substituted pyrimidine derivative.
【請求項2】金属が亜鉛であることを特徴とする請求項
1記載の方法。
2. The method of claim 1 wherein the metal is zinc.
【請求項3】R1はC1〜C5のアルキル基を表し、R2
水素原子を表し、R 3は−CH2−R67で表される基
(R6は酸素原子を表し、R7はメチル基またはヒドロキ
シルメチル基を表す。)で表されることを特徴とする請
求項1または2に記載の方法。
3. R1Is C1~ CFiveRepresents an alkyl group of R,2Is
Represents a hydrogen atom, R 3Is -CH2-R6R7Group represented by
(R6Represents an oxygen atom, R7Is a methyl group or hydroxy
Represents a silmethyl group. ) A contract characterized by being represented by
The method according to claim 1 or 2.
JP6139021A 1994-06-21 1994-06-21 Production of 6-aralkyl substituted pyrimidine derivative Pending JPH083143A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6139021A JPH083143A (en) 1994-06-21 1994-06-21 Production of 6-aralkyl substituted pyrimidine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6139021A JPH083143A (en) 1994-06-21 1994-06-21 Production of 6-aralkyl substituted pyrimidine derivative

Publications (1)

Publication Number Publication Date
JPH083143A true JPH083143A (en) 1996-01-09

Family

ID=15235632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6139021A Pending JPH083143A (en) 1994-06-21 1994-06-21 Production of 6-aralkyl substituted pyrimidine derivative

Country Status (1)

Country Link
JP (1) JPH083143A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779722A1 (en) * 1998-06-15 1999-12-17 Expansia Sa Preparation of 1,5-dialkyl-6- methyl aryl uracil derivatives with improved purity
US8106064B2 (en) 2006-07-24 2012-01-31 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-dione HIV reverse transcriptase inhibitors
US8119800B2 (en) 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779722A1 (en) * 1998-06-15 1999-12-17 Expansia Sa Preparation of 1,5-dialkyl-6- methyl aryl uracil derivatives with improved purity
US8106064B2 (en) 2006-07-24 2012-01-31 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-dione HIV reverse transcriptase inhibitors
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
US8119800B2 (en) 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors

Similar Documents

Publication Publication Date Title
EP0371139B1 (en) 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
ES2923278T3 (en) Useful intermediates for the synthesis of aminopyrimidine derivatives, process for preparing the same and process for preparing aminopyrimidine derivatives using the same
JPH083143A (en) Production of 6-aralkyl substituted pyrimidine derivative
JPH03120279A (en) Novel method
JP3564982B2 (en) 4-Fluoro-3-oxocarboxylic acid ester and method for producing the same
KR19990008411A (en) Improvement method of 4-hydroxy-2-pyrrolidone
JPH10130244A (en) Production of acyclonucleoside
WO2004007418A1 (en) A process for the preparation of 2-acetoxymethyl-4 halo-but-1-yl acetates
JPH10168068A (en) Production of acyclonucleoside
JPS5813550B2 (en) Sinquinapiride (4,3-D) Pyrimidinedione
JP3272340B2 (en) Method for producing 1-[(cyclopent-3-en-1-yl) methyl] -5-ethyl-6- (3,5-dimethylbenzoyl) -2,4-pyrimidinedione
JPH10130245A (en) Production of acyclonucleoside
JP3518627B2 (en) Method for producing optically active 5-hydroxymethyloxazolidinone derivative
JPH0881427A (en) ((4-substituted acetyl-ortho--phenylene)dioxy) diacetic acid derivative and its production
JP2003520762A (en) Preparation of thiobarbituric acid derivatives
JPS5920677B2 (en) Method for producing a novel pyrimido[4,5-d]pyrimidinedione derivative
JPS5813551B2 (en) Sinquinapiride (4,3-D) Pyrimidinedione
JPH07116211B2 (en) Uracil derivative
JPH01294661A (en) Production of 4-acetoxyazetidinone derivative
JPS5813547B2 (en) Cinquinapiride (2,3-D) Pyrimidinedione
EP0066440A1 (en) Chemical process
HU198949B (en) Process for producing 5-substituted-3&#39;azido-2&#39;,3&#39;-dideoxyribonucleosides
JPS5813553B2 (en) Sinquinapiride (4,3-D) Pyrimidinedione
JPS60109595A (en) Imidazole nucleoside derivative and its production
JPS584033B2 (en) Method for producing a novel pyrido[2,3-d]pyrimidine-2-thione derivative